Objective: To investigate the clinic therapeutic effect of sigmoid orthotopic neobladder after radical cystectomy. Methods: Sixteen patients with invasive bladder cancer (all males; age range from 53 to 75 years) were admitted and underwent radical cystectomy and sigmoid orthotopic neobladder. Results: The 16 patients were hospitalized for 37 to 62 d, with an average of 51 d. All the 16 patients were followed up for a mean of 26 months (range from 5 months to 6 years). The serum creatinine and blood urea nitrogen levels were both in the normal range without acidosis in all the cases. No cases had unilateral ureteral urine reflux during cystography. Of the 16 patients 14 cases (87.5%) achieved continence during daytime; 6 cases (37.5%) were incontinent at night, but all of them could control urination by being woken up at night. The capacity of the neobladder was 245 to 380 mL with an average of 316 mL and the maximal pressure of the neobladder during filling was 28 to 57 cmH 2 O (1 cmH 2 O =0.098 kPa) with an average of 39 cmH 2 O. Conclusions: As an operation the sigmoid orthotopic neobladder can be performed easily without serious postoperative complications and more reliable results. This operation may be generally applied in clinical practice.
Objective: Bladder cancer (BCa) is a common malignancy worldwide and has a high probability of recurrence. Early detection is vital to improve the overall survival rate. The common diagnostic modalities, such as cystoscopy and urinary cytology, have their limitations. In this study, potential metabolic biomarkers have been discovered through gas chromatography-mass spectrometry. Based on distinct metabolomics of urine between BCa patients and healthy people, we forged a non-invasive BCa diagnostic model and investigated its performance. Methods: This study includes Training Phase, Modeling Phase and Test Phase. During the Training Phase, urine samples were collected from 32 patients diagnosed of bladder cancer and 21 healthy controls. We applied unsupervised principal component analysis (PCA) and orthogonal partial least-squares discriminant analysis (OPLS-DA) model used as a diagnostic model to distinguish two groups. We further constructed logistic regression model using combinations of the metabolites to improve the sensitivity and specificity for early BCa determination. In addition, we screened metabolites which AUC was more than 0.75 for establishing the model of diagnostic panel using logistic regressive analysis. In Test Phase, urine samples from 79 BCa patients and 51 non-BCa controls were subjected to test the diagnostic model. Moreover, by subgroup analysis of BCa, some metabolites were indentified to associate with tumor grade and stage. Results: In Training phase, a set of 22 candidate differential metabolites was based on statistical significance and fold difference. Logistic diagnostic model has been established as below: Y=1.3333-8.891X(Glycine)×10-8-4.811X (3-Phosphoglycericacid)×10-5-5.625X(Cytosine)×10-5, with Area Under ROC Curve (AUC) =0.88, sensitivity =78.1% and specificity =95.2%. In Test phase, the efficiency of our diagnostic model shown AUC =0.705, sensitivity =62.0% and specificity =72.5%, better than that of urinary cytology.
